These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36394921)

  • 1. Addressing Metabolic Comorbidity in Individuals With Intellectual and Developmental Disability on Antipsychotics: A Clinical Case Series.
    Stogios N; Hahn MK; Lunsky Y; Desarkar P; Agarwal SM
    J Clin Psychopharmacol; 2023 Jan-Feb 01; 43(1):60-63. PubMed ID: 36394921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study.
    Gomes T; Khuu W; Tadrous M; Vigod S; Cobigo V; Lunsky Y
    BMJ Open; 2019 Jul; 9(7):e028125. PubMed ID: 31366646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities.
    Lunsky Y; Khuu W; Tadrous M; Vigod S; Cobigo V; Gomes T
    Can J Psychiatry; 2018 Jun; 63(6):361-369. PubMed ID: 28830241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolic adverse effects of antipsychotic use in individuals with intellectual and/or developmental disability: A systematic review and meta-analysis.
    Smith E; Stogios N; Au E; Maksyutynska K; De R; Ji A; Erlang Sørensen M; St John L; Lin HY; Desarkar P; Lunsky Y; Remington G; Hahn M; Agarwal SM
    Acta Psychiatr Scand; 2022 Sep; 146(3):201-214. PubMed ID: 35894550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescriptions for Antipsychotics: Youth with Intellectual/Developmental Disabilities Compared to Youth without Intellectual/Developmental Disabilities.
    Marquis S; Marquis NE; Lunsky Y; McGrail KM; Baumbusch J
    J Autism Dev Disord; 2024 Apr; ():. PubMed ID: 38678514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of antipsychotics in people with intellectual disability.
    Frighi V; Stephenson MT; Morovat A; Jolley IE; Trivella M; Dudley CA; Anand E; White SJ; Hammond CV; Hockney RA; Barrow B; Shakir R; Goodwin GM
    Br J Psychiatry; 2011 Oct; 199(4):289-95. PubMed ID: 21816867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
    Anagnostou E; Aman MG; Handen BL; Sanders KB; Shui A; Hollway JA; Brian J; Arnold LE; Capano L; Hellings JA; Butter E; Mankad D; Tumuluru R; Kettel J; Newsom CR; Hadjiyannakis S; Peleg N; Odrobina D; McAuliffe-Bellin S; Zakroysky P; Marler S; Wagner A; Wong T; Macklin EA; Veenstra-VanderWeele J
    JAMA Psychiatry; 2016 Sep; 73(9):928-37. PubMed ID: 27556593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance-related and addictive disorders among adults with intellectual and developmental disabilities (IDD): an Ontario population cohort study.
    Lin E; Balogh R; McGarry C; Selick A; Dobranowski K; Wilton AS; Lunsky Y
    BMJ Open; 2016 Sep; 6(9):e011638. PubMed ID: 27591020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials.
    Zheng W; Li XB; Tang YL; Xiang YQ; Wang CY; de Leon J
    J Clin Psychopharmacol; 2015 Oct; 35(5):499-509. PubMed ID: 26280837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies.
    Bushe CJ; Bradley AJ; Doshi S; Karagianis J
    Int J Clin Pract; 2009 Dec; 63(12):1743-61. PubMed ID: 19840151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin for the prevention of clozapine-induced weight gain: A retrospective naturalistic cohort study.
    Stogios N; Maksyutynska K; Navagnanavel J; Sanches M; Powell V; Gerretsen P; Graff-Guerrero A; Chintoh AF; Foussias G; Remington G; Hahn MK; Agarwal SM
    Acta Psychiatr Scand; 2022 Sep; 146(3):190-200. PubMed ID: 35726126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.
    McKee JR; Bodfish JW; Mahorney SL; Heeth WL; Ball MP
    J Clin Psychiatry; 2005 Sep; 66(9):1161-8. PubMed ID: 16187775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-Cause, 30-Day Readmissions Among Persons With Intellectual and Developmental Disabilities and Mental Illness.
    Balogh R; Lin E; Dobranowski K; Selick A; Wilton AS; Lunsky Y
    Psychiatr Serv; 2018 Mar; 69(3):353-357. PubMed ID: 29137556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the evidence for the use of metformin in the treatment of metabolic syndrome caused by antipsychotics.
    Jesus C; Jesus I; Agius M
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S489-91. PubMed ID: 26417824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
    Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
    Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
    Newall H; Myles N; Ward PB; Samaras K; Shiers D; Curtis J
    Int Clin Psychopharmacol; 2012 Mar; 27(2):69-75. PubMed ID: 21979790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.